Pharmacosmos Drug Patent Portfolio
Pharmacosmos owns 2 orange book drugs protected by 19 US patents Given below is the list of Pharmacosmos's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12168666 | Morphic forms of trilaciclib and methods of manufacture thereof | 13 Nov, 2040 | Active |
| US11529352 | Preservation of immune response during chemotherapy regimens | 23 Jul, 2039 | Active |
| US12527798 | 05 Dec, 2037 | Active | |
| US11633489 | Iron carbohydrate complex for treatment of iron deficiency of a fetus or an infant | 22 Jun, 2036 | Active |
| US8598186 | CDK inhibitors | 30 Dec, 2034 | Active |
| US10085992 | Transient protection of normal cells during chemotherapy | 14 Mar, 2034 | Active |
| US10966984 | Transient protection of normal cells during chemotherapy | 14 Mar, 2034 | Active |
| US11717523 | Transient protection of normal cells during chemotherapy | 14 Mar, 2034 | Active |
| US9487530 | Transient protection of normal cells during chemotherapy | 14 Mar, 2034 | Active |
| US10189849 | CDK inhibitors | 25 Oct, 2031 | Active |
| US10189850 | CDK inhibitors | 25 Oct, 2031 | Active |
| US10927120 | CDK inhibitors | 25 Oct, 2031 | Active |
| US11040042 | Transient protection of normal cells during chemotherapy | 25 Oct, 2031 | Active |
| US8598197 | CDK inhibitors | 25 Oct, 2031 | Active |
| US9957276 | CDK inhibitors | 25 Oct, 2031 | Active |
| US8815301 | Stable iron oligosaccharide compound | 14 Aug, 2029 | Active |
| US10414831 | Stable iron oligosaccharide compound | 25 Mar, 2029 | Active |
| US11851504 | Stable iron oligosaccharide compound | 25 Mar, 2029 | Active |
| US12030962 | Stable iron oligosaccharide compound | 25 Mar, 2029 | Active |
Latest Legal Activities on Pharmacosmos's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Pharmacosmos.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Withdrawal of Application for PTE | 23 Oct, 2025 | US9487530 |
| Disposal for a RCE / CPA / R129 | 16 Oct, 2025 | US12527798 |
| Date Forwarded to Examiner | 16 Oct, 2025 | US12527798 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 Oct, 2025 | US9957276 |
| Record Petition Decision of Granted to Withdraw from Issue | 13 Oct, 2025 | US12527798 |
| Mail-Record Petition Decision of Granted to Withdraw from Issue | 13 Oct, 2025 | US12527798 |
| Dispatch to FDC | 13 Oct, 2025 | US12527798 |
| Workflow - Request for RCE - Begin | 13 Oct, 2025 | US12527798 |
| Application Is Considered Ready for Issue | 13 Oct, 2025 | US12527798 |
| Request for Continued Examination (RCE) | 13 Oct, 2025 | US12527798 |
| Petition Entered | 13 Oct, 2025 | US12527798 |
| Mailing Corrected Notice of Allowability | 09 Oct, 2025 | US12527798 |
| Email Notification | 09 Oct, 2025 | US12527798 |
| Issue Fee Payment Received | 09 Oct, 2025 | US12527798 |
| Issue Fee Payment Verified | 09 Oct, 2025 | US12527798 |
Pharmacosmos's Family Patents
Pharmacosmos Drug List
Given below is the complete list of Pharmacosmos's drugs and the patents protecting them.
1. Cosela
Cosela is protected by 14 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12168666 | Morphic forms of trilaciclib and methods of manufacture thereof |
13 Nov, 2040
(14 years from now)
| Active |
| US11529352 | Preservation of immune response during chemotherapy regimens |
23 Jul, 2039
(13 years from now)
| Active |
| US12527798 |
05 Dec, 2037
(11 years from now)
| Active | |
| US8598186 | CDK inhibitors |
30 Dec, 2034
(8 years from now)
| Active |
| US10085992 | Transient protection of normal cells during chemotherapy |
14 Mar, 2034
(7 years from now)
| Active |
| US10966984 | Transient protection of normal cells during chemotherapy |
14 Mar, 2034
(7 years from now)
| Active |
| US11717523 | Transient protection of normal cells during chemotherapy |
14 Mar, 2034
(7 years from now)
| Active |
| US9487530 | Transient protection of normal cells during chemotherapy |
14 Mar, 2034
(7 years from now)
| Active |
| US10189849 | CDK inhibitors |
25 Oct, 2031
(5 years from now)
| Active |
| US10189850 | CDK inhibitors |
25 Oct, 2031
(5 years from now)
| Active |
| US10927120 | CDK inhibitors |
25 Oct, 2031
(5 years from now)
| Active |
| US11040042 | Transient protection of normal cells during chemotherapy |
25 Oct, 2031
(5 years from now)
| Active |
| US8598197 | CDK inhibitors |
25 Oct, 2031
(5 years from now)
| Active |
| US9957276 | CDK inhibitors |
25 Oct, 2031
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cosela's drug page
2. Monoferric
Monoferric is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11633489 | Iron carbohydrate complex for treatment of iron deficiency of a fetus or an infant |
22 Jun, 2036
(10 years from now)
| Active |
| US8815301 | Stable iron oligosaccharide compound |
14 Aug, 2029
(3 years from now)
| Active |
| US10414831 | Stable iron oligosaccharide compound |
25 Mar, 2029
(2 years from now)
| Active |
| US11851504 | Stable iron oligosaccharide compound |
25 Mar, 2029
(2 years from now)
| Active |
| US12030962 | Stable iron oligosaccharide compound |
25 Mar, 2029
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Monoferric's drug page